Neurointerventional Device Update: The Burgeoning Stroke Toolbox

The treatment of acute ischemic stroke and brain aneurysms is rapidly evolving. New transcatheter devices and adjuvant imaging promising to improve outcomes and reduce the burden of neurovascular disease. However, to really spur this market, long-term, large-scale clinical trials are needed.

Approximately 795,000 new or recurrent strokes will occur this year in the US – or one every 40 seconds. And, by 2030, an additional four million Americans will have had a stroke, a 24.9% increase in prevalence from 2010, according to the latest American Heart Association (AHA) projections. Stroke is the fourth leading cause of death in the US, killing 200,000 people each year, and a leading cause of serious long-term adult disability, with over seven million people over age 20 living with the consequences of stroke, according to the AHA. Approximately 87% of strokes are ischemic (caused by a blood vessel blockage in the brain), and as of only a decade ago intravenous therapy with the thrombolytic drug tissue plasminogen activator (tPA) was the only real treatment option for these patients. Now however, minimally invasive, neurointerventional procedures are shifting the treatment paradigm – for ischemic stroke as well as brain aneurysms – and have created promising new device markets that are attracting established, acquisition-minded players as well as innovative start-ups. (See Also see "The Neurovascular Market Tilts Toward A Tipping Point " - Scrip, 1 October, 2011..) A number of positive developments in this space were presented at the Society of NeuroInterventional Surgery (SNIS) 9th Annual Meeting, held in July in San Diego, CA, and so far this year two next-generation mechanical clot-retrieval devices have received US Food and Drug Administration (FDA) approval, with other neurointerventional devices debuting internationally.

According to industry players and researchers in this space, neurointerventional devices to directly address blood clots in the brain are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

EU Medtech Outlook: The View From MedTech Europe Experts

 
• By 

MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.

‘Confident In Lorundrostat’s Promise’: Mineralys CEO Talks Trials And Next Steps

 

In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.

BioBytes: Qubit Pharmaceuticals Unveils Quantum AI Model For Drug Discovery

 
• By 

Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.